Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Pittsburgh, PA
Treatments:ChemotherapyHospital:University of Pittsburgh Cancer Institute
Drugs:Journal:Link
Date:Sep 2013

Description:

Patients:
This study involved squamous cell non-small-cell lung cancer patients who were divided into two separate treatment groups. Group A consisted of 229 patients with a median age of 59 years, 90% of whom were male. Group B had of 221 patients with a median age of 59 years, 90% of whom were male.

Treatment:
Patients in group A were treated with the chemotherapy agents nab-paclitaxel and carboplatin.
Patients in group B were treated with the chemotherapy agents paclitaxel (solvent-based) and carboplatin.

Toxicities:
The most severe toxicities in group A were of grade 4 and included anemia and thrombocytopenia. Grade 3 fatigue and nerve toxicity were also reported.

The most severe toxicities in group B were of grade 4 and included neutropenia and nerve toxicity.

Results:
The median overall survival times for groups A and B were 10.7 and 9.5 months, respectively.

Support:
This study was supported by Celegene, makers of Abraxane (brand name for nab-paclitaxel).

Correspondence: Dr. Mark A. Socinski; email: [email protected]



Back